<DOC>
	<DOCNO>NCT00003779</DOCNO>
	<brief_summary>RATIONALE : Biological therapy BCG use different way stimulate immune system stop cancer cell grow . It yet know type BCG effective bladder cancer . PURPOSE : Randomized phase III trial compare effectiveness two different type BCG treat patient bladder cancer .</brief_summary>
	<brief_title>Biological Therapy Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare two strain BCG ( Connaught v Tice ) term efficacy ( yearly relapse rate ) tolerability patient Ta T1 papillary carcinoma urinary bladder carcinoma situ urinary bladder . II . Assess role prior exposition mycobacteria ( vaccination/Tbc ) BCG treatment efficacy patient . III . Define role fever occurrence potential indicator BCG reactivity patient . IV . Evaluate p53 status resect tumor IL-8 secretion urine predictive factor BCG reactivity patient . V. Evaluate disease free interval disease free survival , time progression , overall survival patient . VI . Evaluate quality life patient . OUTLINE : This randomize , multicenter study . Patients stratify accord center , T stage ( Ta vs T1 v CIS ) , BCG immunization status ( positive , i.e. , great 10 mm diameter v negative-indeterminate , i.e. , less 10 mm diameter ) . All patient undergo complete transurethral resection ( TURB ) remove bladder tumor . A Mantoux test perform . Patients stage T1 disease undergo second resection within 2-4 week initial TURB . Patients randomize receive either BCG Onko-Tice ( arm I ) BCG Connaught ( arm II ) . Both arm receive BCG catheter begin 2-14 day last TURB . Patients must hold BCG bladder 2 hour . BCG instill week 6 week . Quality life assess randomization , daily first last week treatment , every 6 month first 2 year , annually thereafter . Patients follow every 6 month first 3 year , annually thereafter . PROJECTED ACCRUAL : A minimum 300 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm completely resect T1 Ta papillary tumor urinary bladder TaG2 great 2 relapse 2 year TaG3 unifocal multifocal Unifocal primary T1G23 histological tumorfree second resection If multiple/multifocal , bad stage grade AND/OR Histologically cytologically confirm primary secondary carcinoma situ urinary bladder No persistent T1 disease second resection No contract bladder ( bladder capacity le 80 mL ) bladder irritation within past 5 year No urothelial carcinoma upper urinary tract urethra PATIENT CHARACTERISTICS : Age : 18 90 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Liver function great 1.5 time upper limit normal ( ULN ) Renal : Renal function great 1.5 time ULN Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent malignancy except basocellular carcinoma No congenital acquire immunosuppression ( e.g. , HIV , leukemia , lymphoma , transplant recipient ) No uncontrollable untreated urinary tract infection No chronic recur bacterial cystitis PRIOR CONCURRENT THERAPY : Biologic therapy : No prior BCG therapy Chemotherapy : At least 3 month since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 5 year since prior radiotherapy bladder Surgery : See Disease Characteristics Other : No prior tuberculostatic therapy No concurrent local antiseptic antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
</DOC>